Cargando…

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

BACKGROUND: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with oesophagogastric cancer, but leads to high rates of haematological toxicity. Weekly docetaxel is associated with less haematological toxicity. This rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822950/ https://www.ncbi.nlm.nih.gov/pubmed/20068567 http://dx.doi.org/10.1038/sj.bjc.6605522

Ejemplares similares

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
por: Tebbutt, Niall C, et al.
Publicado: (2016)

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
por: Sumpter, K, et al.
Publicado: (2005)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
por: Sjoquist, Katrin M., et al.
Publicado: (2022)

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008)

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2012)

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
por: Mercieca-Bebber, R., et al.
Publicado: (2022)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study
por: de Vries, Yfke C., et al.
Publicado: (2016)

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
por: Lam, Lyn Ley, et al.
Publicado: (2023)

The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2020)

Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer
por: Dassen, Anneriet E, et al.
Publicado: (2016)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

Complete Remission of Advanced Gastric Cancer in Response to Chemotherapy With Docetaxel, Cisplatin and Capecitabine (dcx)
por: Marroqui, Asuncion Juarez, et al.
Publicado: (2011)

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer
por: Korkeila, E. A., et al.
Publicado: (2017)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
por: Siu, Ho Wai Derrick, et al.
Publicado: (2021)

Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
por: Koukourakis, Georgios V., et al.
Publicado: (2008)

A 5-Fluorouracil-Induced Hyperammonemic Encephalopathy Challenged with Capecitabine
por: Chahin, Michael, et al.
Publicado: (2020)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

A qualitative investigation of the supportive care experiences of people living with pancreatic and oesophagogastric cancer
por: Khan, Nadia N., et al.
Publicado: (2022)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study
por: Maeda, Osamu, et al.
Publicado: (2017)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

Successful capecitabine rechallenge following 5-fluorouracil-induced Takotsubo syndrome
por: Abdelrahman, Mohamed, et al.
Publicado: (2016)

Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
por: Peng, Jianjun, et al.
Publicado: (2018)

Meta-Analysis of Capecitabine versus 5-Fluorouracil in Advanced Gastric Cancer
por: Wu, Zhongliang, et al.
Publicado: (2023)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
por: Li, Bo, et al.
Publicado: (2019)

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
por: Rigg, A., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_laen2v5s6vjmkvvek0o6r64krj